{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:58:49Z","timestamp":1781153929094,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.curtheres.2026.100826","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:59:38Z","timestamp":1772121578000},"page":"100826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Proprietary Pharmacovigilance Database"],"prefix":"10.1016","volume":"104","author":[{"given":"Davide","family":"Susini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Crea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Kleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bizzarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2026.100826_bib0001","unstructured":"European Medicines Agency. Accessed August 6, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev-4_en.pdf."},{"issue":"4","key":"10.1016\/j.curtheres.2026.100826_bib0002","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5415\/apallergy.2013.3.4.249","article-title":"Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study","volume":"3","author":"Palabrica","year":"2013","journal-title":"Asia Pac Allergy"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100826_bib0003","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","article-title":"Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients","volume":"40","author":"Jr","year":"2012","journal-title":"Infection"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100826_bib0004","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.24358","article-title":"Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs","volume":"91","author":"Ammann","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.curtheres.2026.100826_bib0005","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.curtheres.2026.100826_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619876736","article-title":"Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study","volume":"10","author":"Elajez","year":"2019","journal-title":"Ther Adv Drug Saf"},{"issue":"10","key":"10.1016\/j.curtheres.2026.100826_bib0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100826_bib0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11239-021-02610-4","article-title":"Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012)","volume":"53","author":"Ammann","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100826_bib0009","first-page":"e635","article-title":"Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.curtheres.2026.100826_bib0010","first-page":"S13","article-title":"The role of isoagglutinins in intravenous immunoglobulin\u2013related hemolysis","volume":"55","author":"Bellac","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.curtheres.2026.100826_bib0011","unstructured":"AgenziaItaliana del Farmaco (AIFA). Riassunto delle Caratteristiche del Prodotto (RCP): ig VENA 50 g\/L soluzione per infusione (immunoglobulina umana normale per uso endovenoso). Rome, Italy: AIFA; 2021. Available from: Agenzia Italiana del Farmaco. (Italian)."},{"key":"10.1016\/j.curtheres.2026.100826_bib0012","unstructured":"European Medicines Agency. Accessed August 22, 2024. https:\/\/medic.co.il\/wp-content\/uploads\/2021\/01\/Ig-Vena_solution-for-infusion_SPC_06-2020-_clean.pdf."},{"key":"10.1016\/j.curtheres.2026.100826_bib0013","unstructured":"European Medicines Agency. Accessed January 29, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-5_en.pdf."},{"key":"10.1016\/j.curtheres.2026.100826_bib0014","unstructured":"European Medicines Agency. Accessed December 18, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf."},{"key":"10.1016\/j.curtheres.2026.100826_bib0015","unstructured":"Kedrion, PSUSA\/00001633\/202505 Periodic Safety Update report. 2025 August 20, 2025."},{"key":"10.1016\/j.curtheres.2026.100826_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420943006","article-title":"Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency","volume":"34","author":"Ricci","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100826_bib0017","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/vox.13046","article-title":"Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products","volume":"116","author":"Wilmot","year":"2021","journal-title":"Vox Sang"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100826_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","article-title":"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk","volume":"38","author":"Dantal","year":"2013","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100826_bib0019","first-page":"567","article-title":"Intravenous immunoglobulin therapy in the treatment of the acute phase of chronic idiopathic thrombocytopenic purpura in adults","volume":"9","author":"Grossi","year":"2006","journal-title":"Haema"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100826_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100826_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/08860220500531286","article-title":"Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy","volume":"28","author":"Chacko","year":"2006","journal-title":"Renal Failure"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100826_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/ped.15362","article-title":"Real-world results with IgPro20 for hypo- or agammaglobulinemia in Japan","volume":"64","author":"Imai","year":"2022","journal-title":"Pediatr Int"},{"issue":"7","key":"10.1016\/j.curtheres.2026.100826_bib0023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1348-0421.12060","article-title":"Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections","volume":"57","author":"G\u00fcnther","year":"2013","journal-title":"Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100826_bib0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2169\/internalmedicine.3661-24","article-title":"Maintenance intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy: 18-month post-marketing surveillance in 103 patients","volume":"64","author":"Kuwabara","year":"2025","journal-title":"Intern Med"},{"key":"10.1016\/j.curtheres.2026.100826_bib0025","article-title":"Maintenance intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy: 18-month post-marketing surveillance in 103 patients","author":"Kuwabara","year":"2024","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100826_bib0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jdermsci.2023.01.004","article-title":"Intravenous immunoglobulin in patients with bullous pemphigoid insufficient response to corticosteroids: nationwide post-marketing surveillance in Japan","volume":"109","author":"Ujiie","year":"2023","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.curtheres.2026.100826_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1260296","article-title":"Real-world experience with CLAIRYG\u00ae 50 mg\/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immune thrombocytopenia: a post-approval safety study","volume":"11","author":"Mahlaoui","year":"2023","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100826_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.345","article-title":"Surveillance study on the tolerability and safety of Flebogamma\u00ae DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients","volume":"5","author":"Alsina","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100826_bib0029","first-page":"192","article-title":"Intravenous immunoglobulin G use and pharmacovigilance in a tertiary care children's hospital. Utilizaci\u00f3n y farmacovigilancia de inmunoglobulina G endovenosa en un hospital pedi\u00e1trico de alta complejidad","volume":"119","author":"Yori","year":"2021","journal-title":"Arch Argent Pediatr"},{"issue":"9","key":"10.1016\/j.curtheres.2026.100826_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5414\/CPP43420","article-title":"Safety monitoring of a polyvalent immunoglobulin preparation: documentation of 15,548 administrations","volume":"43","author":"Struff","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.curtheres.2026.100826_bib0031","doi-asserted-by":"crossref","first-page":"847","DOI":"10.5414\/CP202782","article-title":"Tolerability and safety of Octagam\u00ae (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials","volume":"54","author":"Frenzel","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100826_bib0032","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/nmt-2018-0006","article-title":"Octagam\u00ae for chronic inflammatory demyelinating polyneuropathy: results from three observational studies","volume":"8","author":"Wietek","year":"2018","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.curtheres.2026.100826_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.740517","article-title":"A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion","volume":"12","author":"Kato","year":"2021","journal-title":"Front Immunol"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X2600007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X2600007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:22:00Z","timestamp":1781151720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X2600007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0011393X2600007X"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100826","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Proprietary Pharmacovigilance Database","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100826"}}